ストックスクリーナーアプリを入手
4.99
2.54%
-0.13
アフターアワーズ：
5.00
0.010
+0.20%
前日終値:
$5.12
開ける：
$5.1
24時間の取引高:
474.76K
Relative Volume:
0.76
時価総額：
$67.21M
収益：
-
当期純損益:
$-27.71M
株価収益率:
-1.1709
EPS:
-4.2615
ネットキャッシュフロー:
$-19.77M
1週間 パフォーマンス:
-1.96%
1か月 パフォーマンス:
+11.38%
6か月 パフォーマンス:
+29.27%
1年 パフォーマンス:
+12.13%
1日の値動き範囲:
$4.93
$5.2344
1週間の範囲:
$4.62
$5.30
52週間の値動き範囲:
$3.16
$11.89
Cingulate Inc Stock (CING) Company Profile
Compare CING vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.99 | 67.21M | 0 | -27.71M | -19.77M | -4.2615 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-10 | 開始されました | ROTH MKM | Buy |
| 2023-12-22 | ダウングレード | Laidlaw | Buy → Hold |
Cingulate Inc (CING) 最新ニュース
Why Is CING Stock Jumping Over 4% In Overnight Trading? - Stocktwits
Cingulate Inc (CINGW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cingulate Inc (CINGW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cingulate Inc (CINGW) Institutional Confidence - TradingKey
Cingulate Inc (CINGW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cingulate Inc (CINGW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cingulate Inc (CING) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cingulate Inc (CING) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cingulate Inc (CING) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cingulate Inc (CING) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cingulate Inc (CING) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cingulate Inc (CING) Institutional Confidence - TradingKey
Cingulate Inc (CING) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cingulate Inc (CINGW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cingulate Inc (CINGW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cingulate Inc (CINGW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cingulate Secures First U.S. Patent for CTx-1301 ADHD Drug, Extending Exclusivity to 2042 - Minichart
Cingulate issued U.S. patent for CTx-1301, exclusivity extended into Dec 2042 - TradingView
US patent extends Cingulate (NASDAQ: CING) CTx-1301 ADHD exclusivity - Stock Titan
Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301 - GlobeNewswire
Cingulate Inc (CINGW) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cingulate Inc (CING) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oncology Institute To Rally Over 64%? Here Are 10 Top Analyst Forecasts For Monday - Sahm
CING Q1 2026 Earnings: Wider-than-expected loss as pre-revenue biotech continues pipeline development - newsline.com
Insider Makes Bold Move With Major Cingulate Inc. Stock Purchase - TipRanks
CING Maintained by Ascendiant Capital -- Price Target Lowered to $52 - GuruFocus
Cingulate director Hargroves buys $490,271 of common stock By Investing.com - Investing.com South Africa
Cingulate director Hargroves buys $490,271 of common stock - Investing.com
Cingulate (CING) director-linked LLC buys shares, warrants as options granted - Stock Titan
Cingulate (CING) director reports initial share and warrant holdings - Stock Titan
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (NASDAQ: CING) Following FDA Complete Response Letter - citybuzz -
FDA focuses on manufacturing for Cingulate CTx-1301, not safety - Stock Titan
FDA slaps CRL on Cingulate’s CTx-1301 NDA - The Pharma Letter
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301 - AJMC
FDA Issues Complete Response Letter for Cingulate ADHD Drug CTx-1301 - Patient Care Online
Biopharma bites: FDA rebuffs Cingulate's ADHD hopeful, plus Contraline's male contraceptive funding - FirstWord Pharma
FDA rejects Cingulate's application for ADHD medicine - The Business Journals
FDA Sends Complete Response Letter for Cingulate's CTx-1301 | PharmExec - PharmExec.com
FDA Issues CRL for CTx-1301 in ADHD Over CMC Concerns - HCPLive
Cingulate Gets FDA Request for Updates on ADHD Drug Application - Moomoo
Cingulate Inc - Reuters
Cingulate Inc. Q1 2026 Earnings: Wider-than-Expected Loss, Yet Shares Rally 19%Earnings Preview - thelegaladvocate.com
Cingulate Receives FDA Complete Response Letter for CTx-1301 ADHD Drug; No Clinical Safety or Efficacy Concerns Identified 1 - Minichart
FDA declines to approve Cingulate's ADHD treatment over manufacturing issues - Reuters
FDA Sends CRL to Cingulate for CTx-1301 - PharmExec.com
ADHD drug delivery specialist Cingulate hit with manufacturing-related FDA rejection - Fierce Pharma
Cingulate stock tumbles after FDA issues response letter - Investing.com
Cingulate receives FDA complete response letter for ADHD drug By Investing.com - Investing.com South Africa
Cingulate stock tumbles after FDA issues response letter By Investing.com - Investing.com Australia
Cingulate receives FDA complete response letter for ADHD drug - Investing.com
Cingulate Faces FDA Delay But Maintains ADHD Drug Plans - TipRanks
Cingulate Inc (CING) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):